Form 8-K - Current report:
SEC Accession No. 0001213900-24-000247
Filing Date
2024-01-02
Accepted
2024-01-02 16:04:14
Documents
16
Period of Report
2024-01-02
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea190916-8k_citius.htm   iXBRL 8-K 28797
2 PRESS RELEASE, DATED JANUARY 2, 2024 ea190916ex99-1_citius.htm EX-99.1 83133
3 PRESS RELEASE, DATED JANUARY 2, 2024 ea190916ex99-2_citius.htm EX-99.2 14747
4 GRAPHIC ex99-1_001.jpg GRAPHIC 4472
5 GRAPHIC ex99-2_001.jpg GRAPHIC 4472
  Complete submission text file 0001213900-24-000247.txt   330690

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE ctxr-20240102.xsd EX-101.SCH 3027
7 XBRL LABEL FILE ctxr-20240102_lab.xml EX-101.LAB 34240
8 XBRL PRESENTATION FILE ctxr-20240102_pre.xml EX-101.PRE 22367
10 EXTRACTED XBRL INSTANCE DOCUMENT ea190916-8k_citius_htm.xml XML 3309
Mailing Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016
Business Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 (908) 967-6676
Citius Pharmaceuticals, Inc. (Filer) CIK: 0001506251 (see all company filings)

EIN.: 273425913 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38174 | Film No.: 24502366
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)